Search

Search Constraints

You searched for: Author/Creator Bender, David P.

Search Results

1. Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study. Issue 35 (10th December 2022)

2. Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial. Issue 19 (1st July 2022)

3. Life stress as a risk factor for sustained anxiety and cortisol dysregulation during the first year of survivorship in ovarian cancer. Issue 16 (15th June 2018)

4. Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer. (2nd July 2022)

5. A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix: An NRG Oncology/Gynecologic Oncology Group Study. Issue 3 (1st March 2015)

6. Eudaimonic well‐being and tumor norepinephrine in patients with epithelial ovarian cancer. Issue 19 (10th June 2015)

7. A Phase I-II Evaluation of Veliparib (NSC #737664), Topotecan, and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Carcinoma of the Uterine Cervix. Issue 3 (March 2015)

8. Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. Issue 2 (February 2019)